Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human 4-1BB / TNFRSF9 Protein, Avi Tag (Avitag™), His tag, 25µg  

Recombinant Biotinylated Human 4-1BB / TNFRSF9 Protein, Avi Tag (Avitag™), His tag, 25µg

Biotinylated Human 4-1BB / TNFRSF9, (Leu 24 - Gln 186), expressed from human 293 cells (HEK293), Avi tag (Avitag™), His tag

Synonym
recombinant, human, biotinylated, protein, TNFRSF9,4-1BB,CD137,CDw137

More details

41B-H82E3-25

Availability: within 7 days

420,00 €

Background
4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

Source
Biotinylated Human 4-1BB, Avitag,His Tag (41B-H82E3) is expressed from human 293 cells (HEK293). It contains AA Leu 24 - Gln 186 (Accession # NP_001552.2).
Predicted N-terminus: Leu 24

Molecular Characterization
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag. The protein has a calculated MW of 19.9 kDa. The protein migrates as 28-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
The biotin to protein ratio is 0.5-1 as determined by the HABA assay.

Endotoxin
Less than 1.0 EU per μg by the LAL method.
 
Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Reconstitute at 200 μg/mL in sterile deionized water.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
4-8°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution. 

Bioactivity (ELISA bioactivity)
Immobilized Human 4‑1BB Ligand, Fc Tag (Cat. No. 41L-H5257) at 2 μg/mL (100 μL/well) can bind Biotinylated Human 4-1BB, Avitag,His Tag (Cat. No. 41B-H82E3) with a linear range of 2-31 ng/mL (QC tested).
Immobilized Human 4‑1BB Ligand, His Tag (Cat. No. 41L-H5249) at 2 μg/mL (100 μL/well) can bind Biotinylated Human 4-1BB, Avitag,His Tag (Cat. No. 41B-H82E3) with a linear range of 1-31 ng/mL (Routinely tested).

References

(1) Cooper D, et al., 2002, Eur. J. Immunol. 32 (2): 521–9.
(2) Jang, I K., et al., 1998, Biochem. Biophys. Res. Commun. (UNITED STATES) 242 (3): 613–20.
(3) Arch, R H., Thompson C B., 1998, Mol. Cell. Biol. (UNITED STATES) 18 (1): 558–65.

Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrosbiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.
Commercial use of the Avitag™ technology to manufacture a commercial product, or use of the Avitag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays.